Please assess the completion status of the following clinical trial:

Trial Title: A Study of VIS410 to Assess Safety and Pharmacokinetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers~* Body mass index between 18 and 33 kg/m2, inclusive~* Normal labs~* Volunteers agree to use acceptable contraceptive measures~Exclusion Criteria:~* Prior receipt of antibody or biologic therapy~* History of cancer, heart disease, diabetes, respiratory condition (eg asthma), autoimmune disorder, blood dyscrasias~* Any chronic condition requiring daily prescription or over the counter medication~* History of a previous severe allergic reaction~* Drug or alcohol abuse within previous 12 months~* Positive serology for human immunodeficiency virus (HIV) antibody, hepatitis C virus (HCV) antibody or hepatitis B surface antigen (HBsAg)~* Positive pregnancy test~* Breast feeding~* Positive drug or alcohol test at screening or check-in~* Receipt of licensed vaccine (within 30 days) or other investigational product within 30 days or 5 half-lives, whichever is longer, before study product administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- VIS410 (Type: EXPERIMENTAL): VIS410 administered as a single infusion with ascending dose-escalation ranging from 2 to 50 mg/kg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered as a single infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).